VRTX EBITDA Growth
Vertex Pharmaceuticals · EBITDA Growth
VRTX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported19.92%period ending
VRTX TTM EBITDA YoY % (46.34% → 19.92%)
Year-over-year change
High-resolution chart · PNG
VRTX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 19.9198% | |
| 7,168.5452% | |
| 903.5677% | |
| 800.2704% | |
| 886.7555% | |
| -101.524% | |
| -89.4706% | |
| -88.5333% | |
| -89.686% | |
| 14.5233% | |
| 3.8259% | |
| 6.7699% | |
| 9.1488% | |
| 42.9691% | |
| 52.0258% | |
| 44.2186% | |
| 59.5941% | |
| -11.4074% | |
| -11.1698% | |
| -4.4211% | |
| 8.2079% | |
| 81.973% | |
| 110.4937% | |
| 241.2283% | |
| 151.3527% | |
| 129.3804% | |
| 120.7705% | |
| 13.4954% | |
| 296.7635% | |
| 1,273.7224% | |
| 584.4797% | |
| 4,292.5304% | |
| -40.3381% | |
| -83.0022% | |
| 43.9336% | |
| 174.8164% | |
| 636.3771% | |
| 243.3494% | |
| 117.5534% | |
| 95.2751% | |
| 87.168% | |
| 59.5061% | |
| 37.2156% | |
| 44.6278% | |
| 35.1892% | |
| 20.4566% | |
| 34.6376% | |
| -41.8623% | |
| -69.4663% | |
| -57.485% | |
| -2,450.7317% | |
| -290.8753% | |
| -197.1595% | |
| -227.1331% | |
| -66.7057% | |
| 210.7631% | |
| 175.803% | |
| 152.7722% | |
| 117.6111% | |
| 52.762% | |
| -22.1307% | |
| -27.3312% | |
| -24.5692% | |
| -11.6325% | |
| -4.9089% | |
| -14.5903% | |
| -36.0974% | |
| -53.8715% | |
| -55.3383% | |
| -24.8148% | |
| -10.6367% | |
| -15.3361% | |
| -31.0283% | |
| -72.516% | |
| -93.0713% | |
| -76.8511% | |
| -68.135% | |
| -75.9179% | |
| -67.3298% | |
| -47.0809% | |
| -38.2708% | |
| -15.5728% | |
| -10.8223% | |
| 33.5141% | |
| 52.0121% | |
| 61.6949% | |
| 56.9359% | |
| -9.1028% | |
| -110.3852% | |
| -447.4855% | |
| -165.306% | |
| -131.1905% | |
| -97.6% | |
| 3.8472% | |
| -94.3935% | |
| -42.7509% | |
| -15.215% | |
| -117.8062% | |
| -67.3541% | |
| -301.0805% |